Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up

Human Pathology

Volumn 27, Issue 11, 1996, Pages 1149-1155

  Barbareschi, Mattia ^a   Caffo, Orazio ^b   Veronese, Silvio ^b   Leek, Russel D ^b   Fina, Paolo ^b   Fox, Steven ^b   Bonzanini, Mariella ^b   Girlando, Salvatore ^b   Morelli, Luca ^b   Eccher, Claudio ^b   Pezzella, Francesco ^b   Doglioni, Claudio ^b   Dalla Palma, Paolo ^b   Harris, Adrian ^b  

^a SANTA CHIARA HOSPITAL   (Italy)

^b NONE

Author keywords

Bcl 2; breast cancer; estrogen receptors; human; immunohistochemistry; p53 protein; survival analysis

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GENE PRODUCT; METHOTREXATE; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

ADULT; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; ORAL DRUG ADMINISTRATION; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 16044367682     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90307-X     Document Type: Article

References (50)

1. Korsmaeyer SJ: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80:879-886, 1992
2. Hockenbery DM, Zutter M, Hickey W, et al: Bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88:6961-6965, 1991
3. Sabourin JC, Martin A, Baruch J, et al: Bcl-2 expression in normal breast tissue during menstrual cycle. IntJ Cancer 59:1-6, 1994
4. Doglioni C, Dei Tos AP, Laurino L, et al: The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathologic correlates, with particular reference to estrogen receptor status. Virchows Arch 424:47-51, 1994
5. Leek RD, Kaklamanis L, Pezzella F, et al: Bcl-2 in normal breast and barcinoma, association with estrogen receptor-positive, epidermal growth factor-negative tumours and in situ cancer. Br J Cancer 69:135-139, 1994
6. Bhargava V, Kell DL, van de Rijn M, et al: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540, 1994
7. Gorczyca W, Markiewski M, Kram A, et al: Immunohistochemical analysis of Bcl-2 and p53 expression in breast carcinomas: Their correlation with Ki67 growth fraction. Virchow Arch 426:229-233, 1995
8. Joensuu H, Pylkkanen L, Toikkanen S: Bcl-2 protein expression and long term survival in breast cancer. Am J Pathol 145:1191-1198, 1994
9. Silvestrini R, Veneroni S, Daidone MG, et al: The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994
10. Hellemans P, van Dam PA, Weyler J, et al: Prognostic value of bcl-2 expression in invasive breast cancer. BrJ Cancer 72:354-360, 1995
11. Gee JMW, Robertson JFR, Ellis IO, et al: Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59:619-628, 1994
12. Gasparini G, Barbareschi M, Doglioni C, et al: Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1:189-198, 1995
13. Lane DP: p53: The guardian of the genome. Nature 358:15-16, 1992
14. Haldar S, Negrini M, Monne M, et al: Down-regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095-2097, 1994
15. Miyashita T, Harigai M, Hanada M, et al: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54:3131-3135, 1994
16. Pezzella F, Micklem K, Turley H, et al: Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol 47:592-596, 1994
17. Barbareschi M, Leonardi E, Mauri FA, et al: p53 and c-erbB-2 expression in breast carcinoma: An immunohistochemical study with correlations to receptor status, proliferation markers, and clinical stage in human breast carcinoma. Am J Clin Pathol 98:408-418, 1992
18. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
19. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
20. Silvestrini R, Benini E, Daidone MG, et al: p53 As an independent prognostic marker in lymph node-negative cancer patients. J Natl Cancer Inst 85:965-970, 1993
21. Gasparini G, Weidner N, Bevilacqua P, et al: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454-466, 1994
22. Gasparini G, Pozza F, Harris AL: Methodology of evaluation and potential usefulness of the new biological-related prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993
23. Azzopardi J: Problems in Breast Pathology. London, Saunders, 1979
24. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: The evaluation of histological grade in breast cancer: Experience from a lagre study with long term follow-up. Histopathology 19:403-410, 1991
25. Todd JH, Dowle C, Williams MR, et al: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56:489-492, 1987
26. Dei Tos AP, Doglioni C, Barbareschi M, et al: p53 expression in soft tissue lesions. Histopathology 22:45-50, 1995
27. Veronese S, Barbareschi M, Morelli L, et al: Predictive value of ER1D5 antibody immunostaining in breast cancer: A paraffin-based retrospective study of 257 cases. Appl Immunohistochem 3:85-90, 1995
28. Pereira H, Pinder SE, Sibbering DM, et al: Pathologic prognostic factors in breast cancer. IV. Should you be a typer or a grader? A comparative study of two histological prognostic features inoperable breast carcinoma. Histopathology 27:219-226, 1995
29. Yang E, Zha J, Jockel J, et al: Bad, a heterodimeric partner for Bcl-X1 and Bcl-2, displaces Bax and promotes cell death. Cell 80:285-291, 1995
30. Takayama S, Sato T, Krajewski S, et al: Cloning and functional analysis of BAG-1: A novel Cbl-2 binding protein with anti-cell death activity. Cell 80:279-284, 1995
31. Bargou RC, Daniel PT, Mapara MY, et al: Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-alpha expression in tumor cells correlates with resistence toward apoptosis. Int J Cancer 60:854-859, 1995
32. Johnston SRD, Maclennan KA, Sacks NPM, et al: Modulation of Bcl-2 and Ki67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30A: 1663-1669, 1994
33. Pietenpol JA, Papadopulos N, Markowitz S, et al: Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 54:3714-3717, 1994
34. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
35. Marks JR, Humphrey PA, Wu K, et al: Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 219:332-341, 1994
36. Bosari S, Lee AKC, Viale G, et al: Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long term follow-up. Virchows Arch 421:291-295, 1992
37. Haerslev T, Jacobsen GK; An immunohistochemical study of p53 protein with correlations to histopathological parameters, c-erbB-2: Proliferating cell nuclear antigen, and prognosis. HUM PATHOL 95:26:295-301, 1995
38. Rosen PP, Lesser ML, Arroyo CD, et al: p53 In node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 13:821-830, 1995
39. Lipponen P, Ji H, Aaltomaa S, et al: p53 Protein expression in breast cancer as related to histopathologic characteristics and prognosis. Int J Cancer 55:51-56, 1993
40. Page DL: Prognosis and breast cancer: Recognition of lethal and favourable prognostic types. Am J Surg Pathol 15:334-349, 1991
41. Baak JPA: Mitosis counting in tumors. HUM PATHOL 21:683-685, 1990
42. Biesterfeld S, Noll I, Noll E, et al: Mitotic frequency as a prognostic factor in breast cancer. HUM PATHOL 26:47-52, 1995
43. Page DL, Ellis IO, Elston CW: Histological grading of breast cancer. Am J Clin Pathol 103:123-124, 1995
44. Frierson HF, Wolber R, Berean KW, et al: Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103:195-198, 1995
45. Clark GM: Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 30:117-126, 1994
46. Elledge RM, Gray R, Mansour E, et al: Accumulation of p53 protein as a possible predictor of response to adjuvant therapy with cyclophosphamide, methotrexate, fluoruracil and prednisone for breast cancer. J Natl Cancer Inst 87:1254-12565, 1995
47. Barbareschi M: Prognostic value of the immunohistochemical expression of p53 in breast carcinomas: A review of the literature involving over 9000 patients. Appl Immunohiostochem 4:106-116, 1996
48. Doglioni C, Barbareschi M, Pelosio P: Immunohistochemistry of tumor suppressor gene products. Surg Pathol 6:129-146, 1995
49. Lowe SW, Bodis S, Mcclatchey A, et al: p53 Status and the efficacy of cancer therapy in vivo. Science 266:807-811, 1994
50. WAF1 and p53 expression in breast carcinoma: An immunohistochemical study on 261 cases with long term follow up. Clin Cancer Res 1996 (in press)